US Patent

US8497393 — Process to prepare treprostinil, the active ingredient in Remodulin®

Composition of Matter · Assigned to United Therapeutics Corp · Expires 2028-12-15 · 3y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects an improved process for preparing the active ingredient treprostinil, used in the drug Remodulin.

USPTO Abstract

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

Drugs covered by this patent

Patent Metadata

Patent number
US8497393
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-12-15
Drug substance claim
Yes
Drug product claim
No
Assignee
United Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.